LY 3532226
Alternative Names: LY-3532226Latest Information Update: 21 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Aug 2024 Eli Lilly and Company plans to initiate a phase I trial for Obesity in the US (SC) (NCT06557356)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Singapore (SC)
- 21 Feb 2024 Eli Lilly and Company completes a phase I trial in Type 1 diabetes mellitus in USA (SC) (NCT05887999)